Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 7Phase 3 6Phase NA 4Phase 1/2 4Phase EARLY_PHASE1 2Phase 2/3 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 2Tumor-Agnostic 1Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 78Cyclophosphamide 55Specimen Handling 53Carboplatin 49fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 37Biopsy 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Cisplatin 24Pemetrexed 23Ipilimumab 22Capecitabine 21Temozolomide 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Phantoms, Imaging × 90 days × Clear all
NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
22 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡